Vetoquinol: Availability of the 2019 Universal Registration Document

LURE, France--(BUSINESS WIRE)-- Regulatory News:

Vetoquinol (Paris: VETO) informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

The 2019 Universal Registration Document is available to the public, free of charge under the conditions provided by applicable regulations and may be consulted on the “Investors” page of the Group’s website (www.vetoquinol.com), in the “Regulated Information” section. It is also available on the AMF’s website (www.amf-france.org).

The 2019 Universal Registration Document includes:

• the 2019 Annual Financial Report;
• the Management Report;
• the Board of Directors Report on Corporate Governance;
• the Extra-Financial Performance Declaration;
• the information related to the fees paid to the Statutory Auditors;
• the share buyback program description; and
• the agenda and draft resolutions of the Shareholder’s Meeting of May 26, 2020.

Given the current status as of the date of filing of this Universal Registration Document, updates following the Covid-19 pandemic have been incorporated into this document.

Next update: Shareholders meeting, May 26, 2020 after market close

About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31 2019 Vetoquinol employs 2,372 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

For further information, go to: www.vetoquinol.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005581/en/

VETOQUINOL
Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
[email protected]

KEIMA Communication
Investor and Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
[email protected]

Source: Vetoquinol

You May Also Be Interested In

• Amentum to Support Critical Infrastructure and Platforms Under New Engineering Services Framework
• 5 Best Cryptos to Watch in 2026: Apeing’s Upcoming Launch Could Shake Up the Crypto Presale List
• Cardium Law Selects iManage to Strengthen Document Management and Support Future AI Innovation